JENBURKT PHARMACEUTICALS
|
|
BOM : 524731     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Mild Upward Pledged Shares : None or < 25% |
Apr 25,2024 |
Price(EOD): ₹ 740.00
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 325.60 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
JENBURKT PHARMACEUTICALS | 0.1% | 5.6% | 4.9% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | -2.8% | 50.3% |
CIPLA | 4.5% | -3.1% | 52.8% |
DR REDDYS LABORATORIES | 4.6% | 1.4% | 22.2% |
ZYDUS LIFESCIENCES | 3.1% | -4.1% | 80.4% |
DIVIS LABORATORIES | 4.7% | 10.8% | 18.1% |
MANKIND PHARMA | 2.7% | 12.4% | NA |
TORRENT PHARMACEUTICALS | 6.1% | 5.3% | 66.2% |
LUPIN | 3.1% | -1.1% | 127.4% |
FUNDAMENTAL ANALYSIS OF JENBURKT PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF JENBURKT PHARMACEUTICALS
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
13.36
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 24.45 Cr
[Latest Qtr - Dec2023 - Standalone Results ] 2.67
P/B Calculated based on Book Value of Rs 122.39 Cr
[Latest Year - Mar2023 - Standalone Results ] 2.36
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Dec2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
19% 16% 17% |
SHARE PRICE MOMENTUM OF JENBURKT PHARMACEUTICALS
JENBURKT PHARMACEUTICALS vs SENSEX
DEBT OF JENBURKT PHARMACEUTICALS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
0.02 0.05 0.04 0.04 |
- - - - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF JENBURKT PHARMACEUTICALS
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF JENBURKT PHARMACEUTICALS
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-6.87% -20.98% -17.83% -26.21% |
3.16% 3.07% 1.06% -0.57% |
QtrlyTrend |
-2 | |
Latest Qtr: Dec2023 | ||
Quarterly Result Analysis → |
JENBURKT PHARMACEUTICALS related INDICES
You may also like the below Video Courses
FAQ about JENBURKT PHARMACEUTICALS
Is JENBURKT PHARMACEUTICALS good for long term investment?
As on Apr 25,2024, the Fundamentals of JENBURKT PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of JENBURKT PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is JENBURKT PHARMACEUTICALS UnderValued or OverValued?
As on Apr 25,2024, JENBURKT PHARMACEUTICALS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of JENBURKT PHARMACEUTICALS ?
As on Apr 25,2024, the Intrinsic Value of JENBURKT PHARMACEUTICALS is Rs. 632.98 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 619.28
Fair Value [Median EV / Sales Model] : Rs. 636.79
Fair Value [Median Price / Sales Model] : Rs. 632.98
Estimated Median Fair Value of JENBURKT PHARMACEUTICALS : Rs. 632.98
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.